Stacey and Kevin Sayer on Zoom. Kevin holds up a box with G7 on the side

“Dexcom is Preparing for the Future” CEO Kevin Sayer on G7, the international market, competitors and more

[podcast src=”https://html5-player.libsyn.com/embed/episode/id/23338376/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/3e9ccc/” width=”100%” scrolling=”no” class=”podcast-class” frameborder=”0″ placement=”top” primary_content_url=”http://traffic.libsyn.com/diabetesconnections/Ep_484_Final_Dexcom_Sayer_ADA_2022.mp3″ libsyn_item_id=”23338376″ height=”90″ theme=”custom” custom_color=”3e9ccc” player_use_thumbnail=”use_thumbnail” use_download_link=”use_download_link” download_link_text=”Download” /]Dexcom CEO Kevin Sayer joins Stacey from the American Diabetes Association’s Scientific Sessions with new G7 information, a response to Abbott’s Libre 3 approval, addressing rumors about acquiring another diabetes company and a lot more. This podcast is not intended…